Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 963 for your search:
Start Over
Bosutinib and Inotuzumab Ozogamicin in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0435, NCI-2014-02606, NCT02311998
Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 1 to under 31
Trial IDs: AALL10B1, NCI-2011-02848, CDR0000695252, COG-AALL10B1, NCT01295476
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Phase: Phase II
Type: Treatment
Age: 70 and over
Trial IDs: CYC682-06, NCI-2010-00412, NCT00590187
Ruxolitinib Phosphate in Treating Patients With Adult T-Cell Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0006, NCI-2013-01560, 130006, 335354, P12996, NCT01712659
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Under 30
Trial IDs: AAML11B10, NCI-2011-03802, CDR0000706823, COG-AAML11B10, NCT01407757
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Phase: Phase IV
Type: Treatment
Age: Not specified
Trial IDs: CAMN107A2409, NCI-2013-02332, 2012-003902-28, NCT01735955
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Biological Therapy and Gene Therapy in Improving Immune System Recovery After Stem Cell Transplant in Patients With Hematopoietic Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: DOTTI, NCI-2012-01076, H-28256, NCT01494103
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 75
Trial IDs: OSU-13219, NCI-2014-00763, 2014C0014, NCT02122081
Cellular, Molecular, Genetic, and Genomic Biology Analysis in Tissue Samples From Patients With Hematologic Malignancies
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 75 and under
Trial IDs: 04-C-0102, NCI-2013-02045, 040102, NCT00900393, NCT00923442
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Ipilimumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-537, NCI-2013-00739, 9204, NCT01822509
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 116428, NCI-2014-01414, 2012-003438-18, NCT01767467
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Children and adults
Trial IDs: ABTR02B1, NCI-2009-00325, CDR0000271322, COG-ABTR02B1, NCT01005277
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
WT-1 Analog Peptide Vaccine in Treating Patients with Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-143, NCI-2011-00086, NCT01266083
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Start Over